Roberta Nicoletti

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

Roberta Nicoletti, Salvatore Lopez, Stefania Bellone et al. · Clinical & Experimental Metastasis · 2014 · 65 citations · Full text

Ovarian Carcinosarcomas, Novel Antibody-drug Conjugate, Medicine +8

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients

Marina Bagnoli, Loris De Cecco, Anna Granata et al. · Oncotarget · 2011 · 63 citations · Full text

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer

A Granata, Roberta Nicoletti, Valentina Tinaglia et al. · British Journal of Cancer · 2013 · 53 citations · Full text

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo

Carlton L. Schwab, Diana P. English, Dana M. Roque et al. · Gynecologic Oncology · 2014 · 34 citations

Uterine Serous Carcinoma, Neratinib Shows Efficacy, Medicine +7

14q32/miRNA Clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up‐regulation of BCL11a

Cecilia Agueli, Giuseppe Cammarata, Domenico Salemi et al. · American Journal of Hematology · 2010 · 33 citations · Full text

Engineering, Mirnas Deregulation, Mixed-phenotype Acute Leukemia +20